APETx2 (TFA)

• UNSPSC Description:

  APETx2 TFA, a sea anemone peptide from Anthopleura elegantissima, is a selective and reversible ASIC3 inhibitor, with an IC50 of 63 nM. APETx2 directly inhibits the ASIC3 channel by acting at its external side. APETx2 could reverses acid‐induced and inflammatory pain[1][2].

• Target Antigen:

  Sodium Channel

• Type:

  Peptides

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/apetx2-tfa.html

• Purity:

  98.38

• Smiles:

  OC(C(F)(F)F)=O.O=C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H](CSSC[C@@H]1NC2=O)C(N[C@@H](CO)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CC(C)C)C(NCC(N[C@H]2[C@H](O)C)=O)=O)=O)=O)=O)=O)NC5=O)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC6=CC=C(C=C6)O)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CC9=CC=CC=C9)C(N[C@@H](CC%10=CC=C(C=C%10)O)C(N[C@@H](CCCNC(N)=N)C(N%11[C@@H](CCC%11)C(N[C@@H](CO)C(N[C@@H](CSSC[C@@H](C(N[C@@H]([C@H](O)C)C(N%12[C@@H](CCC%12)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(O)=O)=O)=O)=O)=O)NC1=O)C(N%13[C@@H](CCC%13)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC%14=CC=C(C=C%14)O)C(N[C@@H]([C@H](O)C)C(NCC(N[C@H]5CO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN.OC(C(F)(F)F)=O

• Molecular Weight:

  4675.02

• References & Citations:

  [1]Sylvie Diochot, et al. A New Sea Anemone Peptide, APETx2, Inhibits ASIC3, a Major Acid-Sensitive Channel in Sensory Neurons. EMBO J. 2004 Apr 7;23(7):1516-25.|[2]Jerzy Karczewski, et al. Reversal of Acid-Induced and Inflammatory Pain by the Selective ASIC3 Inhibitor, APETx2. Br J Pharmacol. 2010 Oct;161(4):950-60.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported